A comparison of clinical effectiveness of immune checkpoint inhibitors in patients with stage III and IV advanced melanoma and cutaneous melanoma
Latest Information Update: 17 Jul 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 13 Apr 2022 New trial record
- 04 Apr 2022 Results published in the European Journal of Cancer